“In the first quarter, we’ve seen great interest and increased momentum in the ORCA-2 trial and look forward to completing enrollment by the middle of the year,” commented John Bencich, Chief Executive Officer of Achieve. “We will continue to focus our efforts on execution of the Phase 3, ensuring all required NDA-enabling activities remain on track, and furthering our discussions with potential strategic partners to prepare for cytisinicline commercialization.”
https://achievelifesciences.com/2021...-quarter-2021/
https://achievelifesciences.com/2021...-quarter-2021/
Коментар